Program
Enavogliflozin
Also written as “DWP16001”, “DWP16001 0.3mg” and “DWP16001 Amg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetic Nephropathies, led by Daewoong Pharmaceutical.
Drug pageEnavogliflozin: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewoong Pharmaceutical | 258 open or running | phase 3since Nov 12, 2020 | Nov 29, 2017 | Nov 2027phase 3 · NCT07619833 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 10 earlier studies, Nov 29, 2017 to Jan 5, 2022.
- Jun 9, 2019Named enavogliflozinINNProposed as its International Nonproprietary Name in WHO's List 121 · before, DWP16001
- Jan 9, 20222 phase 3 studies in Diabetes Mellitus, Type 2NCT05376969, NCT05376930
- Jun 8, 2022Phase 1 study in HealthyNCT05414591 · 38 enrolled · Korea, Republic of
- Jul 5, 2022Phase 1 study in Healthy VolunteersNCT05465668 · 43 enrolled · Korea, Republic of
- Jul 12, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05466643 · 240 planned · Korea, Republic of
- Aug 12, 2022Phase 1 study in HealthyNCT05500898 · 53 enrolled
- Aug 16, 2022Phase 3 study in Diabetes MellitusNCT05505994 · 340 enrolled · China
- Jan 17, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05737771 · 40 enrolled · Korea, Republic of
- Feb 8, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05747664 · 24 planned · Korea, Republic of
- Mar 21, 2023Phase 1 study in HealthyNCT05797922 · 32 planned · Korea, Republic of
- Nov 10, 2023Phase 3 study in Diabetes Mellitus, Type 2NCT06141980 · 134 planned
- Sep 10, 2024Phase 3 study in Type 2 Diabetic NephropathyNCT06606093 · 348 planned · Korea, Republic of
- Oct 11, 2024Phase 1 study in HealthyNCT06644404 · 34 planned · Korea, Republic of
- Jul 29, 2025Phase 1 study in HealthyNCT07213310 · 18 enrolled · South Korea
- May 26, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07619833 · 510 planned · South Korea
Ahead
- Nov 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07619833
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07619833Diabetes Mellitus, Type 2 · South Korea | 3 | Not yet recruiting | Nov 2027 | 510 |
| NCT07213310Healthy · South Korea | 1 | Completed | Jan 7, 2026 | 18 |
| NCT06644404Healthy · Korea, Republic of | 1 | Not yet recruiting | Dec 3, 2024 | 34 |
| NCT06606093Type 2 Diabetic Nephropathy · Korea, Republic of | 3 | Not yet recruiting | Sep 1, 2026 | 348 |
| NCT06141980Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | Sep 2025 | 134 |
| NCT05797922Healthy · Korea, Republic of | 1 | Recruiting | May 31, 2023 | 32 |
| NCT05747664Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Recruiting | Apr 30, 2024 | 24 |
| NCT05737771Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | UNKNOWN | Mar 31, 2023 | 40 |
| NCT05505994Diabetes Mellitus · China | 3 | Active, not recruiting | Feb 26, 2024 | 340 |
| NCT05500898Healthy | 1 | UNKNOWN | Oct 31, 2022 | 53 |
| NCT05466643Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Recruiting | Sep 30, 2024 | 240 |
| NCT05465668Healthy Volunteers · Korea, Republic of | 1 | Completed | Aug 16, 2022 | 43 |
| NCT05414591Healthy · Korea, Republic of | 1 | Completed | Aug 1, 2021 | 38 |
| NCT05321732Healthy Volunteers · Korea, Republic of | 1 | UNKNOWN | Aug 2022 | 24 |
| NCT05207176Healthy | 1 | UNKNOWN | Apr 8, 2022 | 24 |
| NCT05376969Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | May 16, 2022 | 159 |
| NCT05376930Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | May 31, 2022 | 63 |
| NCT05192395Healthy · Korea, Republic of | 1 | Completed | May 24, 2022 | 37 |
| NCT04654390Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Dec 17, 2021 | 270 |
| NCT04632862Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Nov 25, 2021 | 140 |
| NCT04343547Healthy · Korea, Republic of | 1 | UNKNOWN | Jul 2020 | 34 |
| NCT04221399Type2 Diabetes | 1 | UNKNOWN | Aug 2020 | 35 |
| NCT04064073Healthy · Korea, Republic of | 1 | Completed | Nov 20, 2019 | 34 |
| NCT04014023Diabetes Mellitus, Type 2 · Korea, Republic of | 2 | UNKNOWN | Mar 2020 | 196 |
| NCT03364985Healthy · Korea, Republic of | 1 | Completed | May 21, 2019 | 123 |
How it is read
Names in the registry
- “DWP16001”, 18 entries
- “DWP16001 0.3mg”, 3 entries
- “DWP16001 Amg”, 2 entries
- “DWP16001 0.3 mg”, 1 entry
- “DWP16001 Drug A”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 12 studies
- Diabetic Nephropathies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.